ArticleRadiation oncology (London, England)2025
Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bladder-sparing chemoradiotherapy following neoadjuvant chemotherapy for muscle-invasive bladder cancer: a retrospective cohort study.BMC urology · 2026Article
- Intersection of Precision Nutrition and Bladder Cancer: A Narrative State-of-the-Art Review of Potential Applications and Challenges.Journal of clinical medicine · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgroundRadical cystectomy is the recommended treatment in muscle-invasive bladder cancer patients with hydronephrosis. However, there is no literature on the impact of chemoradiotherapy on pre-existing hydronephrosis or the development of new hydronephrosis. This study aims to assess the incidence, aetiology, and management of hydronephrosis before and after chemoradiotherapy (CRT). MATERIALS AND
methodsRetrospective cohort study, including patients with muscle-invasive bladder cancer (MIBC) treated with CRT between 1 January 2014 and 5 December 2022. Patients with urethral urothelial carcinoma and with stage T1 were included if they received total bladder irradiation. Exclusion criteria were renal transplantation, ureteral reimplantation, sequential chemotherapy and radiotherapy, CRT as preoperative treatment, urinary diversion before CRT, transitioning to palliative radiotherapy, and sarcomatoid or signet ring cell carcinoma type. Patients were also excluded if no follow-up data was available. In this period 181 patients received CRT, after applying the exclusion criteria a total of 146 patients were eligible for evaluation. The main outcome was hydronephrosis, defined as any grade of dilatation of the renal pelvis with or without ureter dilatation, identified on any form of imaging.
results146 patients were included, 27 with pre-existing hydronephrosis before CRT and 119 without. The mean age of the patients was 73 years (Standard deviation (SD): 8.59) and 74% was male. Hydronephrosis in patients with pre-existing hydronephrosis persisted after CRT in 74% (n = 20), with 44% (n = 12) receiving drainage. Of the patients without pre-existing hydronephrosis, 21% (n = 25) developed hydronephrosis, and 52% (n = 13) of the patients that developed hydronephrosis required drainage. Tumour was responsible for pre-existing hydronephrosis in 93% (n = 25) and for hydronephrosis after CRT in 22% (n = 6) with pre-existing hydronephrosis. In patients without pre-existing hydronephrosis, hydronephrosis was caused by a tumour in 11 out of 25 patients.
conclusionsPre-existing hydronephrosis persists after CRT for MIBC in ~ 75% of patients and ~ 20% of patients without pre-existing hydronephrosis develops hydronephrosis after CRT. Around half of these patients receive drainage. These findings may assist in counselling patients with pre-existing hydronephrosis regarding the potential outcomes following CRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.